Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702996 | 1.00 | AR (0.42) | ARPGRKDM4EMEN1USP2 | |
| SCHEMBL1702843 | 0.92 | AR (0.40) | ARPGRIKBKBHDAC2HDAC1 | |
| SCHEMBL1702839 | 0.92 | AR (0.40) | ARPGRIKBKBHDAC2HDAC1 | |
| SCHEMBL1702847 | 0.82 | AR (0.45) | ARALDH1A1SMN1; SMN2 | |
| SCHEMBL1702851 | 0.82 | AR (0.45) | ARALDH1A1SMN1; SMN2 | |
| SCHEMBL30436667 | 0.81 | AR (0.50) | ARPGRALDH1A1MAPTHPGD | |
| SCHEMBL524308 | 0.81 | AR (0.50) | ARPGRALDH1A1MAPTHPGD | |
| SCHEMBL12469677 | 0.81 | SMN1; SMN2 (0.54) | ARALDH1A1ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL524307 | 0.81 | AR (0.50) | ARPGRALDH1A1MAPTHPGD | |
| SCHEMBL15168736 | 0.81 | SMN1; SMN2 (0.54) | ARALDH1A1ALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627627-B1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2627643-B1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-8969550-B2 | Process for the synthesis of cyclic carbamates | LONZA LTD. (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8957204-B2 | Process for the synthesis of cyclic carbamates | LONZA LTD. (CH) | 2015-02-17 | — | — | US | disclosed |
| EP-2627642-B1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | LONZA LTD (CH) | 2013-12-05 | — | — | US | disclosed |
| US-20130217875-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2013-08-22 | — | — | US | disclosed |
| US-20130211077-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2013-08-15 | — | — | US | disclosed |
| EP-2447247-A1 | Process for the synthesis of chiral propargylic alcohols | Lonza Ltd. (CH) | 2012-05-02 | — | — | EP | disclosed |
| EP-2447255-A1 | Process for the synthesis of cyclic carbamates | Lonza Ltd. (CH) | 2012-05-02 | — | — | EP | disclosed |
| EP-2441759-A1 | Process for the synthesis of cyclic carbamates | Lonza Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | ADH1C, ADH1A, ADH5 | AR 3033/4885PGR 2209/4885KDM4E 2173/4885 |
| US-20130217875-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | PLCG2, PLCG1, CPS1 | AR 3636/4885PGR 825/4885KDM4E 1989/4885 |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | ADH1C, ADH1A, ADH5 | AR 3033/4885PGR 2209/4885KDM4E 2173/4885 |
| US-20130211077-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | PLCG2, PLCG1, PLCB1 | AR 2944/4885PGR 1815/4885KDM4E 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.